ClinicalTrials.gg
Not yet recruitingNCT07350174Updated Mar 3, 2026

Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis

A Phase 2 interventional study of HRZE and HRZE plus Alpe375 in Tuberculosis Meningitis, sponsored by BioVersys AG. Not yet recruiting. Open to participants aged 15 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by BioVersys AG · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
15 Years to 64 Years
Sex
All
01

Study summary

AlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity. The current trial aims to assess the plasma and CSF PK, as well as the safety and tolerability of alpibectir and three doses of Eto in patients with newly diagnosed TBM. Additionally, it is attended to investigate the effect of AlpE on the PK and efficacy of DTG during the first month of antiretroviral treatment (ART) for Human Immunodeficiency Virus (HIV)-positive patients.

02

Conditions studied

  • Tuberculosis Meningitis

Keywords

  • Tuberculosis, AlpE, Ethionamide, CSF, pharmacokinetics
03

In context

Tuberculosis, Meningeal

31 studies on the registry are indexed under Tuberculosis, Meningeal; 9 are open to participants now.

This study's planned enrollment of 64 is below the median of 125 across 24 interventional studies indexed under Tuberculosis, Meningeal.

Browse Tuberculosis, Meningeal studies →

Lead sponsor

BioVersys AG is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 15 years and \< 65 years
  2. Diagnosis of TBM defined as "definite" or "probable", using criteria proposed by the Tuberculosis Meningitis International Research Consortium.

    • Definite TBM is defined by at least one of the following criteria: acid-fast bacilli (AFB) seen in CSF microscopy, positive CSF M. tuberculosis culture, or positive CSF M. tuberculosis commercial nucleic acid amplification test in the setting of symptoms suggestive of meningitis.
    • Probable TBM is defined using a modified Marais score* Probable TBM: total score* ≥ 12 when neuroimaging is available, or ≥ 10 when neuroimaging is not available. At least 2 points should come from CSF or 2 points from cerebral imaging criteria.

    (*see Appendix 2: Modified Marais Score)

  3. signed by the patient. For patients with Glasgow Coma Scale (GCS) \< 15, the consent of a next of kin/relative will be required, in accordance with applicable local laws and regulations. Deferred consent will be obtained from the participant when their level of consciousness improves, and they have capacity to provide consent. For adolescents below the age of civil majority (as defined in each country), the consent of at least one parent or legal guardian and the assent of the adolescent will be required.

Exclusion criteria

Exclusion Criteria:

  1. Having received >14 days of HRZE TB treatment.
  2. In people with infection: use of antiretroviral treatment (ART) other than efavirenz- or dolutegravir-based.
  3. Glasgow Coma Scale \< 10.
  4. Body weight measured or estimated: \< 40 kg or > 90 kg or > 40 kg/m2.
  5. Renal failure ( \< 30 mL/min, calculated by CKD-EPI formula).
  6. (ALT) > 5 times the .
  7. Clinical evidence of liver failure or decompensated cirrhosis.
  8. For women of , one or more of the following:

    1. Being pregnant, breast-feeding, or intending to breast-feed or conceive a child during the study or within 30 days after the end of treatment visit (D56), OR;
    2. Not willing or able to use highly effective methods (as defined per Appendix 7) starting at screening and continuing until 30 days after the end of treatment visit (D56).
  9. For male participants: intending to conceive a child or not willing or able to consistently use a barrier method e.g. condoms during all sexual activity from inclusion until 90 days after the end of treatment visit (D56).

    Note: Male participants should be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse.

  10. Documented Mtb resistance to rifampicin.
  11. Positive Gram-stain, bacterial culture other than Mtb or cryptococcal antigen in the CSF.
  12. For HIV positive patients: Presence of cryptococcal antigen in the blood.
  13. Inability to collect CSF or to lumbar puncture (LP).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Active comparator
    Group 1: HRZE

    Drug: HRZE

  • Experimental
    Group 2: HRZE plus Alpe375

    Drug: HRZE plus Alpe375

  • Experimental
    Group 3: HRZE plud AlpE500

    Drug: HRZE plus AlpE500

  • Experimental
    Group 4: HRZE plus AlpE625

    Drug: HRZE plus AlpE625

Interventions

  • DrugHRZE

    Drug pages: IsoniazidStudies of IsoniazidIsoniazid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RifampinStudies of RifampinRifampin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PyrazinamideStudies of PyrazinamidePyrazinamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EthambutolStudies of EthambutolEthambutol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Isoniazid (5 mg/kg/day); Rifampicin (10 mg/kg/day); Pyrazinamide (30 mg/kg/day); Ethambutol (20 mg/kg/day).

  • DrugHRZE plus Alpe375

    isoniazid (5 mg/kg/day); rifampicin (10 mg/kg/day); pyrazinamide (30 mg/kg/day); ethambutol (20 mg/kg/day), Alpe375 (alpibectir (30 mg/day), ethionamide (375 mg/day))

  • DrugHRZE plus AlpE500

    isoniazid (5 mg/kg/day); rifampicin (10 mg/kg/day); pyrazinamide (30 mg/kg/day); ethambutol (20 mg/kg/day), Alpe375 (alpibectir (30 mg/day), ethionamide (500 mg/day))

  • DrugHRZE plus AlpE625

    isoniazid (5 mg/kg/day); rifampicin (10 mg/kg/day); pyrazinamide (30 mg/kg/day); ethambutol (20 mg/kg/day), Alpe375 (alpibectir (30 mg/day), ethionamide (625 mg/day))

06

What researchers measure

Primary outcomes

  1. To describe the pharmacokinetics (PK) of AlpE in plasma and cerebrospinal fluid (CSF) in patients with newly diagnosed Tuberculosis Meningitis (TBM)

    CSF/plasma ratio of alpibectir, ethionamide and the metabolite ethionamide sulfoxide

    Time frame: 15 days

Secondary outcomes

  1. To assess the safety and tolerability of alpibectir and ethionamide (Eto) in patients with TBM

    Incidence of adverse events (AEs), including AEs ≥ grade 3, serious adverse events (SAEs), and AEs leading to AlpE discontinuation between D1 and D56

    Time frame: 56 days

Other outcomes

  1. To assess the effect of AlpE on the plasma PK of isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E) (HRZE).

    CSF/plasma ratio of HRZE

    Time frame: Day 15

  2. To assess the Mycobacterium tuberculosis (Mtb) culture conversion rate

    To estimate the Mycobacterium tuberculosis (Mtb) culture conversion rate and time to detection (by MGIT), and cycle threshold (GeneXpert MTB/RIF Ultra) on the CSF and respiratory samples at screening, D3, and D15.

    Time frame: 15 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Mar 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 20, 2026
StartEst.
Mar 30, 2026
Primary completionEst.
Mar 30, 2028
CompletionEst.
Oct 30, 2028
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07350174
Lead sponsor
BioVersys AG
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Mar 30, 2026 (estimated)
Primary completion
Mar 30, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Mar 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion